| Identification | More | [Name]
Nomegestrol 17-acetate | [CAS]
58652-20-3 | [Synonyms]
17ALPHA-ACETOXY-6ALPHA-METHYL-19-NOR-PREGN-4,6-DIEN-3,20-DIONE
17-hydroxy-6-methyl-19-norpregna-4,6-diene-3,20-dione 17-acetate
MELEGESTROL ACETATE
nomegestrol 17-acetate
NOMEGESTROL ACETATE
17-alpha-acetoxy-6-methyl-19-nor-4,6-pregnadiene-3,20-dione
17-alpha-hydroxy-6-methyl-19-norpregna-4,6-diene-3,20-dioneacetate
20-dione,17-(acetyloxy)-6-methyl-19-norpregna-6-diene-3
6-diene-3,20-dione,17-alpha-hydroxy-6-methyl-19-norpregna-acetate
tx066
3,20-Dioxo-6-methyl-19-norpregna-4,6-dien-17-ol acetate
NOMAC
Nomegsetrol acetate | [EINECS(EC#)]
261-379-8 | [Molecular Formula]
C23H30O4 | [MDL Number]
MFCD00941390 | [Molecular Weight]
370.48 | [MOL File]
58652-20-3.mol |
| Chemical Properties | Back Directory | [Appearance]
White or almost white, crystalline powder. | [Boiling point ]
507.3±50.0 °C(Predicted) | [density ]
1.16±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: ≥7mg/mL | [form ]
powder | [color ]
white to tan | [InChI]
InChI=1S/C23H30O4/c1-13-11-20-18(17-6-5-16(26)12-19(13)17)7-9-22(4)21(20)8-10-23(22,14(2)24)27-15(3)25/h11-12,17-18,20-21H,5-10H2,1-4H3/t17-,18-,20-,21+,22+,23+/m1/s1 | [InChIKey]
IIVBFTNIGYRNQY-YQLZSBIMSA-N | [SMILES]
C1(=O)C=C2[C@]([H])(CC1)[C@]1([H])[C@]([H])([C@@]3([H])[C@@](CC1)(C)[C@@](OC(C)=O)(C(=O)C)CC3)C=C2C | [CAS DataBase Reference]
58652-20-3(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Chemical Properties]
White or almost white, crystalline powder. | [Uses]
Contraceptive | [Uses]
Nomegestrol 17-acetate is a progetin used in implantable hormone replacement therapies.
| [Definition]
ChEBI: Nomegestrol acetate is a corticosteroid hormone. | [in vivo]
Nomegestrol acetate (50, 100, 200 mg/kg; p.o.; single daily for 28 days) inhibits growth of RL95-2 xenograft tumors in vivo[1].
Nomegestrol acetate (100, 200 mg/kg; p.o.; single daily for 28 days) surpresses the expression of SUFU and Wnt7a in tumor tissues[1].
Nomegestrol acetate (1, 2.5 mg/rat; p.o.; single daily for 4 days) inhibits ovulation in rats[2]. | Animal Model: | Female athymic nude mice (BALB/c; 18-20 g; 6 to 7-week-old; xenograft nude mouse model)[1]. | | Dosage: | 50, 100, 200 mg/kg | | Administration: | Oral gavage; single daily for 28 days | | Result: | Reduced the growth of RL95-2 xenograft tumors in vivo.
Upregulated the expression of SUFU and Wnt7a in a dose-dependent manner when at 100 and 200 mg/kg.
|
| Animal Model: | Mature female Wistar rats (~200 g)[2]. | | Dosage: | 1, 2.5 mg/rat | | Administration: | Oral administration; single daily for 4 days | | Result: | Showed only one animal ovulated after receiving 1 mg/kg per day, and no animals ovulated after receiving 2.5 mg/rat per day. |
|
|
|